Clinical trial
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic…
NCT00189774 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00189774 |
|---|---|
| Title | Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Ajinomoto USA, INC. Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type II |
| Intervention type | Drug |
| Interventions | nateglinide |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 13, 2008 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: